Interventional Cardiology Highlights: FDA commissioner's fiery speech | FFR-guided PCI | P2Y12 inhibitor monotherapy

News You Need to Know Today

Wednesday, October 12, 2022

Editor's Choice: Interventional Cardiology

FDA Commissioner Robert Califf delivers fiery speech on innovation, healthcare disparities and misinformation at TCT 2022

“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

TCT 2022 Robert Califf FDA Commissioner. Robert Califf, MD, the 25th commissioner of the U.S. Food and Drug Administration (FDA), delivered the keynote address in front of a packed room of cardiologists, surgeons and medical device manufacturers. A cardiologist himself—and an adjunct professor of cardiology at the Duke University School of Medicine. He spoke on innovation in cardiology and the need to stop misinformation..

FDA Commissioner Robert Califf delivers fiery speech on innovation, healthcare disparities and misinformation at TCT 2022

“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

FFR-angiography guided lesion selection for PCI improves two-year outcomes in TCT late-breaker

Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.

Example of QFR technology, which uses a rotation of the C-arm around the patient to create a 3D model and a color coded map showing the FFR values and drops in blood flow.

FFR-angiography guided lesion selection for PCI improves two-year outcomes in TCT late-breaker

Impella heart pumps boost survival up to 81% for cardiogenic shock patients

The heart pumps appear to provide significant benefits for patients with acute myocardial infarction- or myocarditis-related cardiogenic shock.

High-risk percutaneous coronary intervention (PCI) with an Impella heart pump is associated with better outcomes, including a significantly higher survival rate, than high-risk PCI with an intra-aortic balloon pump (IABP), according to new findings published in the American Journal of Cardiology. Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Impella heart pumps boost survival up to 81% for cardiogenic shock patients

The heart pumps appear to provide significant benefits for patients with acute myocardial infarction- or myocarditis-related cardiogenic shock.

FFR-guided PCI provides significant value, new meta-analysis confirms

FFR-guided PCI was associated with improved resource utilization and less radiation exposure, among other benefits, when compared to angiography-guided procedures.

$Using fractional flow reserve (FFR) measurements to guide percutaneous coronary intervention (PCI) procedures for patients presenting with multivessel coronary artery disease (CAD) is associated fewer stent implantations, according to a new meta-analysis published in the American Journal of Cardiology. The study’s authors also emphasized that FFR-guided PCI can help improve resource utilization by identifying lesions that do not require treatment.$

FFR-guided PCI provides significant value, new meta-analysis confirms

FFR-guided PCI was associated with improved resource utilization and less radiation exposure, among other benefits, when compared to angiography-guided procedures.

P2Y12 inhibitor monotherapy after PCI similar to prolonged DAPT, new 3-year analysis confirms

Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years.

Interventional cardiologists performing PCI

P2Y12 inhibitor monotherapy after PCI similar to prolonged DAPT, new 3-year analysis confirms

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

Is IVL equally effective in male and female patients? Shockwave Medical aims to find out with a historic new study

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD trial prsented at SCAI 2022. #DisruptPAD, #DisruptCAD, #SCAI #SCAI22 #SCAI2022

Is IVL equally effective in male and female patients? Shockwave Medical aims to find out with a historic new study

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us | Unsubscribe from all | Privacy Policy

© Innovate Healthcare, a TriMed Media brand

Editor's Choice: Interventional Cardiology

Recent Newsletters